Trial Profile
Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Wuzhong Pharmaceutical Group
- 12 Apr 2017 Status changed from recruiting to completed.
- 25 Jan 2017 Planned number of patients changed from 540 to 560.
- 24 Jan 2017 Planned End Date changed from 31 Aug 2014 to 31 Jan 2017.